... of the biopharmaceutical company's stock worth $100,000 after acquiring an additional 140 shares during the period. Ardsley Advisory Partners grew its stake in shares of CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory Partners ...
http://ift.tt/2n1GgAR
No comments:
Post a Comment